H&H Group delivers revenue growth across all three business segments for 2022 and expects positive outlook for 2023

• Reported income development of 10.6% with income of RMB12,775.9 million and adjusted EBITDA development of 6.5% regardless of important headwinds
• Child Vitamin and Care phase returned to development (+1.1% on a like-for-like foundation), turnaround of the probiotics enterprise and stabilising the toddler milk formulation (IMF) enterprise in mainland China
• Grownup Vitamin and Care phase achieved sturdy development of 12.5%, with Swisse persevering with to be the no.1 participant in mainland China’s on-line VHMS market and rising market share within the Australia and New Zealand (ANZ) market in 2022
• Pet Vitamin and Care phase noticed 20.9%[1] general development, led by North America which is now our third-largest market and a serious supply of development
• 98.5% of adjusted EBITDA was transformed into working money circulate, because of the Group’s excessive money era enterprise mannequin which is able to assist to deleverage the stability sheet whereas persevering with to drive development throughout the enterprise
• Maintained steady annual dividend pay-out ratio of fifty% to reward shareholders
• Important strides in sustainability progress together with sustaining Morgan Stanley Capital Worldwide (MSCI) ESG score of ‘A’ and Hong Kong High quality Assurance Company (HKQAA) score of ‘A’ for ESG efficiency

Main world household diet firm Well being and Happiness (H&H) Worldwide Holdings Restricted (inventory code: 1112.HK) has introduced its 2022 annual outcomes, delivering uninterrupted top-line development and like-for-like (LFL) growth, and attaining optimistic EBITDA throughout all three enterprise segments: Child Vitamin and Care (BNC), Grownup Vitamin and Care (ANC), and Pet Vitamin and Care (PNC).

H&H Group

H&H Group

Akash Bedi, Interim Chief Govt Officer and Chief Technique & Operations Officer, says, “I am happy to announce that in 2022, on account of our adaptable and agile enterprise construction and well-implemented methods, the Group demonstrated resilience and achieved sturdy outcomes. We made important progress in delivering worthwhile development by way of our long-term technique, which focuses on profitable in core, globalisation and diversification, and investing in future development alternatives. Our final imaginative and prescient is to turn into a world chief in household diet and wellness, providing superior merchandise and aspirational manufacturers.”

Mr Bedi continued, “In 2022, the Group gained new customers throughout our key markets, in addition to increasing into new markets, whereas persevering with to drive model development by way of consumer-led innovation. We additionally accelerated our sustainability efforts, aiming to ship long-term enterprise development with a optimistic affect on our group members, stakeholders, communities, and the setting. This cultivates an impact-driven mindset and reinforces our goal as a accountable and purpose-led organisation.”

Mainland China
Mainland China accounted for 74.9% of the Group’s complete income in 2022, attaining development of 6.4% on a LFL foundation. Biostime’s branded probiotics additionally noticed spectacular income development of 12.8% in comparison with 2021, solidifying its place because the no. 1 model within the mainland China probiotics market[2]. Our super-premium Biostime IMF phase additionally had a promising yr, with a market share of 12.1% and optimistic retail scan gross sales development, outperforming the general market development price.

Mr Bedi feedback, “I’m happy that regardless of market challenges as a result of declining delivery charges and constrained demand, our IMF enterprise in mainland China has stabilised and we efficiently rotated our probiotics enterprise, whereas remaining the no.1 model of youngsters’s probiotics worldwide.”

Mr Bedi cites consumer-led innovation and engagement as enjoying key roles in Biostime’s success in 2022.

“We launched next-generation new merchandise with a concentrate on partaking our customers reminiscent of Biostime Kids’s Milk Powder and probiotics containing lactoferrin – a significant part of the human immune system. As well as, Biostime has launched ground-breaking analysis on goat milk LPN, which demonstrates the modern and breakthrough outcomes of Biostime’s goat milk powder by way of key immune-boosting elements.”

The ANC phase skilled income development of 14.1%, accounting for 64.4% of the whole ANC income. Swisse ranked because the primary model within the Vitamin, Herb, and Mineral Complement (VHMS) on-line market in mainland China, with a market share of seven.5% (up from 6.6% in 2021), pushed by its new model positioning and introduction of modern merchandise. Swisse’s model picture was revamped to ‘Swisse, Pure and Wholesome, Our New Vogue’, whereas the launch of the Swisse Plus premium vary catered to the wants of high-end Chinese language customers, that includes superior NAD+ merchandise and ldl cholesterol safety dietary supplements.

In 2022, the PNC phase made important progress in mainland China, with Stable Gold already rating because the quantity two model within the premium dry cat meals class, holding a 14.7% market share, regardless of its latest entry into the market. Stable Gold targeted on refreshing its model picture and launched new merchandise within the Chinese language market, increasing its presence to roughly 7,600 pet shops and pet hospitals offline. In December 2022, Zesty Paws was launched in mainland China by way of cross-border e-commerce.

Australia & New Zealand (ANZ)
Within the ANZ market, the ANC phase maintained double-digit income development (+11.7% on a LFL foundation) with promising income development in all channels and an general market share of 12.3%[3]. Swisse outpaced development within the home market with retail scan gross sales development of 12.9% vs 7.4% business development within the twelve months ended 31 December 2022.

Mr Bedi feedback, “The expansion was fuelled by rising demand for immune and wellness merchandise, together with new merchandise led by the launch of the extremely acclaimed Swisse Collagen + Hyaluronic Acid Booster, which has shortly turn into the no.1 magnificence innovation available in the market.”

“We additionally noticed success with Biostime in ANZ in 2022 with the launch of Biostime ready-to-feed (RTF). As well as, we’re proud that our Australian Biostime Human Milk Oligosaccharides (HMOs) product vary gained the NutraIngredients Asia 2022 Editors Award for greatest toddler and youngster diet initiative.”

North America
“After finishing the acquisition of Zesty Paws in 2021, our focus in 2022 was on integrating the model and our PNC phase additional into our enterprise. Consequently, North America has turn into a big supply of development for our Group and is now our third largest market, largely as a result of success of our PNC phase,” provides Mr Bedi.
In 2022, Stable Gold and Zesty Paws achieved a reported income development of 152.5% in North America. Whole income for North America additionally elevated by 18.9% on a like-for-like foundation.

Zesty Paws stays the no.1 pet complement model in the US within the e-commerce channel with 11.5%[4] market share. Zesty Paws and Stable Gold continued to broaden their distribution attain throughout the market together with into main chains reminiscent of Walmart, Goal, PetSmart in addition to unbiased pet shops, and are actually current in additional than 7,700 and three,400 shops, respectively.

Innovation was a core focus with the launch of the premium Stable Gold NutrientBoost vary and useful treats and toppers and new Zesty Paws Vet Power, Dental Bones and Pet merchandise.

Different Territories
Income from different territories was down 6.9% on a LFL foundation, accounting for 4.6% of the Group’s complete income. This was primarily as a result of strategic restructuring within the European markets placing strain on gross sales.

In Asia (excluding mainland China), the Group grew 39.0% on a LFL foundation with phenomenal development momentum in growth markets together with Vietnam, Thailand, India and Malaysia, pushed by distribution positive aspects (each in on-line and offline channels). Hong Kong SAR and Singapore reached sturdy home VHMS market share and contributed positively to development with EBITDA margins on par with the general ANC phase. Swisse additionally reached no.1 Magnificence from inside model in Singapore.

Mr Bedi says, “In Europe, we’re very proud that we maintained management within the French market, whereas specializing in enhancing model consciousness and celebrating new product launches. Biostime bolstered its no.1 place in each natural IMF in French pharmacy with 41.7%[5] market share and in Goat IMF with 41.5%[6] market share. In Italy, we’re happy to see that Swisse is now ranked no.2 within the Magnificence VHMS market with 9.3%[7] market share.”

Sustainability Progress
Mr Bedi says the Group is dedicated to driving enterprise efficiency whereas making a optimistic affect on its group members, stakeholders, communities, and the planet.

“In 2022, we made important progress in our sustainability initiatives, attaining our sustainability objectives and driving shared worth by way of our 4 core affect areas. This contains ‘Advancing the Story for Good Well being,’ ‘Decreasing our Footprint on the Planet,’ ‘Honouring Human Rights and Equity,’ and ‘Supporting Good Governance.’ We additionally maintained our ‘A’ score for ESG efficiency from MSCI and the HKQAA.”

In 2022, the H&H Board established an ESG Committee to refine its governance framework and oversee ESG dangers and alternatives.

H&H has made important progress in the direction of its sustainability objectives in 2022. The corporate accomplished a Group-wide carbon footprint evaluation for Scopes 1, 2, and three and developed science-based greenhouse gasoline emissions discount targets, to be submitted to the Science Based mostly Targets initiative (SBTi). The Group additionally lowered water consumption depth in owned manufacturing services by 18.9% per unit produced, demonstrating its continued efforts to preserve pure assets. Embedding circularity into its merchandise and enterprise fashions has additionally been a key focus, with 98% of its packaging now being recyclable, biodegradable, or compostable. Examples of innovation on this space embrace the Swisse Earth vary in Australia, which makes use of award-winning packaging made out of as much as 70% recycled content material, and initiatives to scale back the usage of virgin packaging, reminiscent of decreasing the dimensions of vials for sure Swisse merchandise.

2023 Outlook
Waiting for 2023, Mr Bedi feedback that the Group stays optimistic because it strives for development, world growth, and diversification.

“One among our major priorities will probably be to pursue natural development methods in each established and new markets, while additionally emphasising the significance of “profitable in core” to drive profitability and development. We anticipate continued development in mainland China, with quicker growth in North America and different Asian markets with optimistic EBITDA. Moreover, we’ll concentrate on decreasing debt ranges and deleveraging its stability sheet to realize a more healthy monetary standing.”

The Group will prioritise the stabilisation of its IMF enterprise by specializing in development within the super-premium class, gaining market share in mainland China, and strengthening its place as the highest probiotics market share holder for each current and new merchandise. In February 2023, the Group obtained approval for the brand new ‘GB requirements’ for the Biostime Alpha Star IMF collection and stays assured in regards to the approval of different collection whereas having deliberate our stock based mostly on the estimated approval timing and buyer demand.

The first focus for the ANC phase in mainland China will probably be to retain its main place, whereas rising its market share in cross-border e-commerce. Together with this, the Group will goal for double-digit development within the regular commerce market, constructing on its present no.4 rating with 2.0%[8] market share. Moreover, the phase goals to raise Swisse’s product portfolio by increasing into new product ranges like Swisse Plus. The precedence within the ANZ market will probably be to achieve market share and regain its home management place, whereas Asia and Europe will think about driving greater development and enhancing profitability.

For PNC in mainland China, the Group’s major goal is to extend market share for Stable Gold within the premium cat meals class. In North America, the Group goals to broaden Zesty Paws’ on-line management on Amazon and Chewy whereas selectively rising in offline channels to extend class penetration. The Group additionally plans to realize worthwhile development for Stable Gold by specializing in the super-premium class and increasing throughout e-commerce.

The Group will proceed to combine sustainability into its core technique and company governance, collaborating with the ESG Committee to determine important long-term sustainability tendencies that may form the longer term and affect the enterprise, thus enabling sustainable and long-term development.

The 2022 Annual Outcomes announcement is offered here.

[1] The LFL change of PNC phase and North America are on professional forma foundation as if the income of Zesty Paws for the twelve months ended 31 December 2022 and 2021 had been consolidated
[2] Kantar Shopper Panel, LTM 31 December 2022
[3] Market share information from IQVIA, LTM 31 December 2022
[4] Stackline, YTD 31 December 2022
[5] GERS, LTM 31 December 2022
[6] IQVIA, LTM 31 December 2022
[7] IQVIA, LTM 31 December 2022
[8] Early Knowledge, LTM 31 December 2022

For media inquiries, contact:

H&H Group
Annabel Jenkins
+44 7514535600

Suppose Alliance Group
Matthew Schultz
+852 3481 1161

By admin